6.70

3.04% -0.21

Kyntra Bio Inc (KYNB)

Overview News Price History Discussions Forecast

Kyntra Bio Inc stock is traded at $6.70, with a volume of 15,594. It is down -3.04% in the last 24 hours and down -1.90% over the past month. Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.

Previous Close:

$6.91

Open:

$6.84

24h Volume:

15,594

Relative Volume:

0.71

Market Cap:

$27.12M

Revenue:

$7.44M

Net Income/Loss:

$-56.57M

P/E Ratio:

0.2439

EPS:

27.467

Net Cash Flow:

$-21.40M

1W Performance:

-0.89%

1M Performance:

-1.90%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$6.6533

$6.85

1-Week Range:

$6.6533

$7.95

52-Week Range:

$6.32

$9.58

Kyntra Bio Inc Stock (KYNB) Company Profile

Name

Kyntra Bio Inc

Sector

Healthcare (1104)

Industry

Biotechnology (617)

Phone

415-978-1200

Address

350 BAY STREET, SAN FRANCISCO

Employee

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

KYNB's Discussions on Twitter

Compare KYNB vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KYNB Kyntra Bio Inc	6.70	27.12M	7.44M	-56.57M	-21.40M	27.47
VRTX Vertex Pharmaceuticals Inc	451.63	114.63B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	609.94	63.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.72	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	278.09	37.13B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	162.99	34.65B	742.00K	-1.37B	-1.07B	-7.0731

Kyntra Bio Inc Stock (KYNB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-08-23	Downgrade	BofA Securities	Neutral → Underperform
Jun-26-23	Downgrade	BofA Securities	Buy → Neutral
Jun-26-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jun-26-23	Downgrade	Stifel	Buy → Hold
Jun-26-23	Downgrade	William Blair	Outperform → Mkt Perform
Jun-02-23	Upgrade	Stifel	Hold → Buy
Jan-31-23	Upgrade	William Blair	Mkt Perform → Outperform
Jan-26-23	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-05-23	Upgrade	BofA Securities	Neutral → Buy
Sep-22-21	Downgrade	Goldman	Neutral → Sell
Aug-20-21	Upgrade	Raymond James	Underperform → Mkt Perform
Jul-16-21	Downgrade	BofA Securities	Buy → Neutral
Jul-16-21	Downgrade	Stifel	Buy → Hold
Apr-07-21	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-07-21	Downgrade	Mizuho	Buy → Neutral
Mar-31-21	Upgrade	BofA Securities	Neutral → Buy
Mar-02-21	Downgrade	Jefferies	Buy → Hold
Feb-01-21	Initiated	H.C. Wainwright	Buy
Oct-26-20	Initiated	Raymond James	Underperform
Jul-10-20	Resumed	Stifel	Buy

View All

Kyntra Bio Inc Stock (KYNB) Latest News

Jun 18, 2026

Kyntra Bio, Inc. Statistics – DUS:1FG0 - TradingView

Jun 18, 2026

Basic earnings per share (basic EPS) of Kyntra Bio, Inc. – DUS:1FG0 - TradingView

Jun 18, 2026

Jun 17, 2026

Kyntra Bio (KYNB) awards 7,000 stock options to director - Stock Titan

Jun 17, 2026

Kyntra Bio (KYNB) director receives 7,000 options at $7.13 strike - Stock Titan

Jun 17, 2026

Jun 16, 2026

Kyntra Bio, Inc. 8-K SEC Filing Details June 12, 2026 – Company Information, Address, and Stock Listing - Minichart

Jun 16, 2026

Kyntra Bio shareholders elect director and approve executive pay at annual meeting - Investing.com

Jun 16, 2026

Kyntra Bio Shareholders Back Board, Pay and Auditor - TipRanks

Jun 16, 2026

Jun 15, 2026

Kyntra Bio (NASDAQ: KYNB) investors back board, pay and PwC auditor - Stock Titan

Jun 15, 2026

Kyntra Bio Inc. Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineLong-Term Guidance - newsline.com

Jun 15, 2026

Jun 14, 2026

Kyntra Bio Inc. Q1 2026 Earnings: Pre‑Revenue Biotech Posts Wider‑Than‑Expected Loss, Stock Gains 5.47% - newsline.com

Jun 14, 2026

Jun 13, 2026